$22.42
+0.13
(+0.58%)▲
1.34%
Downside
Day's Volatility :3.32%
Upside
2.01%
18.78%
Downside
52 Weeks Volatility :65.52%
Upside
57.55%
Period | Schrodinger Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -7.01% | 6.5% | 0.0% |
6 Months | -18.02% | 7.1% | 0.0% |
1 Year | -54.09% | 9.8% | 0.0% |
3 Years | -67.34% | 14.2% | -20.2% |
Market Capitalization | 1.6B |
Book Value | $7.07 |
Earnings Per Share (EPS) | -2.0 |
Wall Street Target Price | 35.36 |
Profit Margin | -75.94% |
Operating Margin TTM | -184.25% |
Return On Assets TTM | -17.0% |
Return On Equity TTM | -25.93% |
Revenue TTM | 188.5M |
Revenue Per Share TTM | 2.62 |
Quarterly Revenue Growth YOY | -43.5% |
Gross Profit TTM | 101.0M |
EBITDA | -209.2M |
Diluted Eps TTM | -2.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.78 |
EPS Estimate Next Year | -2.22 |
EPS Estimate Current Quarter | -0.75 |
EPS Estimate Next Quarter | -0.82 |
What analysts predicted
Upside of 57.72%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 66.6M | ↑ 19.65% |
Net Income | -28.4M | ↑ 63.44% |
Net Profit Margin | -42.66% | ↓ 11.43% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 85.5M | ↑ 28.37% |
Net Income | -25.7M | ↓ 9.65% |
Net Profit Margin | -30.02% | ↑ 12.64% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 108.1M | ↑ 26.36% |
Net Income | -26.6M | ↑ 3.72% |
Net Profit Margin | -24.64% | ↑ 5.38% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 137.9M | ↑ 27.6% |
Net Income | -101.2M | ↑ 279.99% |
Net Profit Margin | -73.38% | ↓ 48.74% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 181.0M | ↑ 31.19% |
Net Income | -149.2M | ↑ 47.39% |
Net Profit Margin | -82.45% | ↓ 9.07% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 216.7M | ↑ 19.73% |
Net Income | 40.7M | ↓ 127.29% |
Net Profit Margin | 18.79% | ↑ 101.24% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 56.8M | ↑ 53.71% |
Net Income | -27.2M | ↓ 31.73% |
Net Profit Margin | -47.87% | ↑ 59.91% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 64.8M | ↑ 13.97% |
Net Income | 129.1M | ↓ 574.63% |
Net Profit Margin | 199.34% | ↑ 247.21% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 35.2M | ↓ 45.68% |
Net Income | 4.3M | ↓ 96.69% |
Net Profit Margin | 12.16% | ↓ 187.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 42.6M | ↑ 20.97% |
Net Income | -62.0M | ↓ 1549.84% |
Net Profit Margin | -145.7% | ↓ 157.86% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 74.1M | ↑ 74.13% |
Net Income | -30.7M | ↓ 50.55% |
Net Profit Margin | -41.38% | ↑ 104.32% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 36.6M | ↓ 50.63% |
Net Income | -54.7M | ↑ 78.43% |
Net Profit Margin | -149.53% | ↓ 108.15% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 120.7M | ↑ 108.08% |
Total Liabilities | 192.3M | ↑ 86.0% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 155.3M | ↑ 28.61% |
Total Liabilities | 248.6M | ↑ 29.28% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 746.3M | ↑ 380.62% |
Total Liabilities | 122.2M | ↓ 50.83% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 756.5M | ↑ 1.37% |
Total Liabilities | 199.4M | ↑ 63.12% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 688.6M | ↓ 8.98% |
Total Liabilities | 240.7M | ↑ 20.7% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 803.0M | ↑ 16.61% |
Total Liabilities | 254.4M | ↑ 5.7% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 688.6M | ↑ 4.02% |
Total Liabilities | 240.7M | ↑ 21.03% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 838.8M | ↑ 21.81% |
Total Liabilities | 248.5M | ↑ 3.25% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 841.6M | ↑ 0.33% |
Total Liabilities | 230.3M | ↓ 7.31% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 794.1M | ↓ 5.63% |
Total Liabilities | 230.6M | ↑ 0.1% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 803.0M | ↑ 1.11% |
Total Liabilities | 254.4M | ↑ 10.34% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 737.8M | ↓ 8.12% |
Total Liabilities | 224.1M | ↓ 11.93% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -23.7M | ↑ 54.9% |
Investing Cash Flow | 11.2M | ↑ 446.32% |
Financing Cash Flow | 80.3M | ↑ 7010.1% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.1M | ↑ 9.9% |
Investing Cash Flow | -53.9M | ↓ 581.11% |
Financing Cash Flow | 28.7M | ↓ 64.27% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 16.8M | ↓ 164.3% |
Investing Cash Flow | -381.7M | ↑ 608.79% |
Financing Cash Flow | 541.3M | ↑ 1787.02% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -70.7M | ↓ 521.73% |
Investing Cash Flow | -16.8M | ↓ 95.6% |
Financing Cash Flow | 8.0M | ↓ 98.53% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -119.7M | ↑ 69.36% |
Investing Cash Flow | 90.0M | ↓ 635.47% |
Financing Cash Flow | 2.1M | ↓ 73.47% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -24.9M | ↓ 17.85% |
Investing Cash Flow | 11.6M | ↑ 47.41% |
Financing Cash Flow | 482.0K | ↑ 48.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -31.1M | ↑ 24.67% |
Investing Cash Flow | 172.2M | ↑ 1390.02% |
Financing Cash Flow | 867.0K | ↑ 79.88% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.4M | ↓ 40.69% |
Investing Cash Flow | 67.2M | ↓ 60.95% |
Financing Cash Flow | 4.5M | ↑ 421.8% |
Sell
Neutral
Buy
Schrodinger Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Schrodinger Inc | 19.52% | -18.02% | -54.09% | -67.34% | -22.17% |
![]() Solventum Corp | 13.4% | -16.71% | -16.71% | -16.71% | -16.71% |
![]() Veeva Systems Inc. | 1.24% | -10.63% | -7.18% | -43.19% | 9.43% |
![]() Ge Healthcare Technologies Inc. | 2.46% | 9.25% | 3.22% | 32.12% | 32.12% |
![]() Healthequity Inc | -3.68% | 3.76% | 26.99% | 6.89% | -2.18% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Schrodinger Inc | 43.22 | NA | NA | -2.78 | -0.26 | -0.17 | NA | 7.07 |
![]() Solventum Corp | NA | NA | NA | 6.26 | 0.17 | 0.08 | NA | NA |
![]() Veeva Systems Inc. | 54.35 | 54.35 | 1.35 | 4.76 | 0.13 | 0.06 | NA | 30.25 |
![]() Ge Healthcare Technologies Inc. | 23.5 | 23.5 | 20.11 | 4.27 | 0.22 | 0.06 | 0.0 | 16.23 |
![]() Healthequity Inc | 85.91 | 85.91 | 2.29 | 2.19 | 0.04 | 0.03 | NA | 24.11 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Schrodinger Inc | Buy | $1.6B | -22.17% | 43.22 | -75.94% |
![]() Solventum Corp | Hold | $10.8B | -16.71% | NA | 15.73% |
![]() Veeva Systems Inc. | Buy | $29.8B | 9.43% | 54.35 | 22.34% |
![]() Ge Healthcare Technologies Inc. | Buy | $36.9B | 32.12% | 23.5 | 8.05% |
![]() Healthequity Inc | Buy | $6.9B | -2.18% | 85.91 | 7.71% |
Insights on Schrodinger Inc
Revenue is down for the last 2 quarters, 74.12M → 36.59M (in $), with an average decrease of 50.6% per quarter
Netprofit is down for the last 2 quarters, -30.67M → -54.72M (in $), with an average decrease of 78.4% per quarter
In the last 1 year, Healthequity Inc has given 27.0% return, outperforming this stock by 81.1%
In the last 3 years, Healthequity Inc has given 6.9% return, outperforming this stock by 74.2%
BlackRock Inc
Gates Bill & Melinda Foundation
Vanguard Group Inc
Baillie Gifford & Co Limited.
ARK Investment Management LLC
Sumitomo Mitsui Trust Holdings Inc
schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. the predictive power of schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries that might otherwise not be possible. schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech company nimbus therapeutics. through significant long-term investments in basic research, schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. hundreds of peer-reviewed scientific publications by schrödinger scientists are frequently among the most heavily cited in their fields. founded in 1990, schrödinger has operations in the us, europe, japan, and india, with business part
Organization | Schrodinger Inc |
Employees | 867 |
CEO | Dr. Ramy Farid Ph.D. |
Industry | Technology Services |
A Spac I Acquisition Corp
$22.42
+0.58%
Keyarch Acquisition Corp
$22.42
+0.58%
Connexa Sports Technologies Inc
$22.42
+0.58%
Us Value Etf
$22.42
+0.58%
First Wave Biopharma Inc
$22.42
+0.58%
Global X Msci Next Emerging
$22.42
+0.58%
Fat Projects Acquisition Corp
$22.42
+0.58%
Capital Link Global Fintech
$22.42
+0.58%
Applied Uv Inc
$22.42
+0.58%